Tg Therapeutics Inc Earnings

Tg Therapeutics Inc’s revenue jumped 90.4% since last year same period to $120.86Mn in the Q1 2025. On a quarterly growth basis, Tg Therapeutics Inc has generated 11.71% jump in its revenue since last 3-months.

Tg Therapeutics Inc’s net profit jumped 147.26% since last year same period to $5.06Mn in the Q1 2025. On a quarterly growth basis, Tg Therapeutics Inc has generated -78.31% fall in its net profits since last 3-months.

Tg Therapeutics Inc’s net profit margin jumped 124.82% since last year same period to 4.19% in the Q1 2025. On a quarterly growth basis, Tg Therapeutics Inc has generated -80.59% fall in its net profit margins since last 3-months.

Tg Therapeutics Inc’s price-to-earnings ratio after this Q1 2025 earnings stands at 144.08.

Tg Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.17 - a 93.33% jump from last quarter’s estimates.

Tg Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at 0.17.

Tg Therapeutics Inc’s earning per share (EPS) jumped 142.86% since last year same period to 0.03 in the Q1 2025. This indicates that the Tg Therapeutics Inc has generated 142.86% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tg Therapeutics Inc’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tg Therapeutics Inc’s return on equity (ROE) stands at 0.2.